Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
130 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Acinetobacter Infections - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acinetobacter Infections - Pipeline Review, H2 2016, provides an overview of the Acinetobacter Infections (Infectious Disease) pipeline landscape. Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, urinary tract). Symptoms include fever (high body temperature), red, swollen, warm or painful skin areas or wounds. Predisposing factors include weak immune system, poor hygiene and recent surgery or procedure. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acinetobacter Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acinetobacter Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Acinetobacter Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 1, 31 and 18 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 4 molecules, respectively for Acinetobacter Infections. Acinetobacter Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Acinetobacter Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Acinetobacter Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Acinetobacter Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Acinetobacter Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Acinetobacter Infections (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Acinetobacter Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Acinetobacter Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Acinetobacter Infections Overview 8 Therapeutics Development 9 Pipeline Products for Acinetobacter Infections - Overview 9 Pipeline Products for Acinetobacter Infections - Comparative Analysis 10 Acinetobacter Infections - Therapeutics under Development by Companies 11 Acinetobacter Infections - Therapeutics under Investigation by Universities/Institutes 13 Acinetobacter Infections - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Acinetobacter Infections - Products under Development by Companies 17 Acinetobacter Infections - Products under Investigation by Universities/Institutes 20 Acinetobacter Infections - Companies Involved in Therapeutics Development 21 Achaogen Inc. 21 Adenium Biotech ApS 22 Aridis Pharmaceuticals LLC 23 AstraZeneca Plc 24 AvidBiotics Corp. 25 Cellceutix Corporation 26 Emergent BioSolutions Inc. 27 Entasis Therapeutics Inc 28 Evaxion Biotech ApS 29 F. Hoffmann-La Roche Ltd. 30 FOB Synthesis, Inc. 31 Hsiri Therapeutics, LLC 32 LegoChem Biosciences, Inc 33 Melinta Therapeutics, Inc 34 MicuRx Pharmaceuticals, Inc. 35 Nosopharm SAS 36 Novabiotics Limited 37 Omnia Molecular Ltd. 38 Peptilogics, Inc. 39 Pfizer Inc. 40 Sarepta Therapeutics, Inc. 41 Sealife PHARMA GMBH 42 Shionogi & Co., Ltd. 43 Techulon, Inc. 44 Tetraphase Pharmaceuticals Inc. 45 Varinel, Inc. 46 Vaxdyn, S.L. 47 Xellia Pharmaceuticals ApS 48 Acinetobacter Infections - Therapeutics Assessment 49 Assessment by Monotherapy Products 49 Assessment by Target 50 Assessment by Mechanism of Action 52 Assessment by Route of Administration 54 Assessment by Molecule Type 56 Drug Profiles 58 A-3APO - Drug Profile 58 AA-139 - Drug Profile 60 ACHN-975 Prodrug - Drug Profile 61 Acinetobacter vaccine - Drug Profile 62 Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile 63 Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile 64 AR-401 - Drug Profile 65 AvR2-V10 - Drug Profile 66 CA-824 - Drug Profile 68 ETX-2514 - Drug Profile 69 EV-035 - Drug Profile 70 Fab-001 - Drug Profile 72 FSI-1671 - Drug Profile 73 FSI-1686 - Drug Profile 74 GN-4474 - Drug Profile 75 HT-06 - Drug Profile 76 HT-07 - Drug Profile 77 HT-10 - Drug Profile 78 LCB-010200 - Drug Profile 79 LCB-100200 - Drug Profile 80 MDN-0057 - Drug Profile 81 Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile 83 MRX-V - Drug Profile 84 NOSO-95179 - Drug Profile 85 NP-432 - Drug Profile 86 OM-011818 - Drug Profile 87 Peptides for Infectious Diseases - Drug Profile 88 PMX-100 - Drug Profile 89 PMX-1091 - Drug Profile 90 PMX-1142 - Drug Profile 91 PMX-229 - Drug Profile 92 PMX-633 - Drug Profile 93 pneumonia vaccine - Drug Profile 94 RX-05 - Drug Profile 95 RXP-873 - Drug Profile 96 S-649266 - Drug Profile 97 SLP-0901 - Drug Profile 99 SLP-0905 - Drug Profile 100 Small Molecule for Acinetobacter baumannii Infections - Drug Profile 101 Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile 102 Small Molecule to Target Bacterial Cell Membrane for Acinetobacter Infections - Drug Profile 103 Small Molecules for Acinetobacter baumannii Infection - Drug Profile 104 Small Molecules for Acinetobacter Infections - Drug Profile 105 Small Molecules for Bacterial Infections - Drug Profile 106 Small Molecules for Bacterial Infections - Drug Profile 107 Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 108 Small Molecules to Inhibit Aminoacyl-tRNA Synthetases for Bacterial Infections - Drug Profile 109 Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile 110 Small Molecules to Inhibit NDH-1 for Acinetobacter baumannii Infections - Drug Profile 111 SPR-741 - Drug Profile 112 Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile 113 TP-6076 - Drug Profile 114 VAR-10100 - Drug Profile 115 VXD-001 - Drug Profile 116 VXD-003 - Drug Profile 117 XEL-1001 - Drug Profile 118 XEL-1002 - Drug Profile 119 XEL-1003 - Drug Profile 120 XEL-1007 - Drug Profile 121 Acinetobacter Infections - Dormant Projects 122 Acinetobacter Infections - Product Development Milestones 124 Featured News & Press Releases 124 Appendix 125 Methodology 125 Coverage 125 Secondary Research 125 Primary Research 125 Expert Panel Validation 125 Contact Us 125 Disclaimer 126
List of Tables
Number of Products under Development for Acinetobacter Infections, H2 2016 13 Number of Products under Development for Acinetobacter Infections - Comparative Analysis, H2 2016 14 Number of Products under Development by Companies, H2 2016 15 Number of Products under Development by Companies, H2 2016 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H2 2016 17 Comparative Analysis by Late Stage Development, H2 2016 18 Comparative Analysis by Clinical Stage Development, H2 2016 19 Comparative Analysis by Early Stage Development, H2 2016 20 Products under Development by Companies, H2 2016 21 Products under Development by Companies, H2 2016 (Contd..1) 22 Products under Development by Companies, H2 2016 (Contd..2) 23 Products under Investigation by Universities/Institutes, H2 2016 24 Acinetobacter Infections - Pipeline by Achaogen Inc., H2 2016 25 Acinetobacter Infections - Pipeline by Adenium Biotech ApS, H2 2016 26 Acinetobacter Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2016 27 Acinetobacter Infections - Pipeline by AstraZeneca Plc, H2 2016 28 Acinetobacter Infections - Pipeline by AvidBiotics Corp., H2 2016 29 Acinetobacter Infections - Pipeline by Cellceutix Corporation, H2 2016 30 Acinetobacter Infections - Pipeline by Emergent BioSolutions Inc., H2 2016 31 Acinetobacter Infections - Pipeline by Entasis Therapeutics Inc, H2 2016 32 Acinetobacter Infections - Pipeline by Evaxion Biotech ApS, H2 2016 33 Acinetobacter Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 34 Acinetobacter Infections - Pipeline by FOB Synthesis, Inc., H2 2016 35 Acinetobacter Infections - Pipeline by Hsiri Therapeutics, LLC, H2 2016 36 Acinetobacter Infections - Pipeline by LegoChem Biosciences, Inc, H2 2016 37 Acinetobacter Infections - Pipeline by Melinta Therapeutics, Inc, H2 2016 38 Acinetobacter Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2016 39 Acinetobacter Infections - Pipeline by Nosopharm SAS, H2 2016 40 Acinetobacter Infections - Pipeline by Novabiotics Limited, H2 2016 41 Acinetobacter Infections - Pipeline by Omnia Molecular Ltd., H2 2016 42 Acinetobacter Infections - Pipeline by Peptilogics, Inc., H2 2016 43 Acinetobacter Infections - Pipeline by Pfizer Inc., H2 2016 44 Acinetobacter Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2016 45 Acinetobacter Infections - Pipeline by Sealife PHARMA GMBH, H2 2016 46 Acinetobacter Infections - Pipeline by Shionogi & Co., Ltd., H2 2016 47 Acinetobacter Infections - Pipeline by Techulon, Inc., H2 2016 48 Acinetobacter Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2016 49 Acinetobacter Infections - Pipeline by Varinel, Inc., H2 2016 50 Acinetobacter Infections - Pipeline by Vaxdyn, S.L., H2 2016 51 Acinetobacter Infections - Pipeline by Xellia Pharmaceuticals ApS, H2 2016 52 Assessment by Monotherapy Products, H2 2016 53 Number of Products by Stage and Target, H2 2016 55 Number of Products by Stage and Mechanism of Action, H2 2016 57 Number of Products by Stage and Route of Administration, H2 2016 59 Number of Products by Stage and Molecule Type, H2 2016 61 Acinetobacter Infections - Dormant Projects, H2 2016 126 Acinetobacter Infections - Dormant Projects (Contd..1), H2 2016 127
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
